The NCAPG2 antibody is a research tool designed to detect the Non-SMC Condensin II Complex Subunit G2 (NCAPG2), a key component of the condensin II complex involved in chromosome organization and segregation during mitosis. NCAPG2 plays a critical role in maintaining genomic stability by ensuring proper chromosome condensation and sister chromatid resolution. Dysregulation of NCAPG2 has been linked to chromosomal instability, mitotic errors, and cancer progression, making it a target for studying tumorigenesis and cell cycle mechanisms.
As a reagent, NCAPG2 antibodies are typically produced in hosts like rabbits or mice using immunogenic peptides or recombinant protein fragments. They are validated for applications such as Western blotting, immunofluorescence, and immunohistochemistry to assess NCAPG2 expression, localization, and dynamics in cells or tissues. Specificity is confirmed via knockout/knockdown controls or blocking assays.
In research, these antibodies help explore NCAPG2's role in diseases, particularly cancers (e.g., hepatocellular carcinoma, lung cancer), where overexpression correlates with poor prognosis. They also aid in studying condensin II's interaction with other mitotic regulators. Commercial NCAPG2 antibodies vary in clonality, epitope recognition, and conjugation, enabling flexibility in experimental design. Proper validation remains essential to ensure reliability in diverse biological contexts.